AMRN - アマリン (Amarin Corporation plc) アマリン

 AMRNのチャート


 AMRNの企業情報

symbol AMRN
会社名 Amarin Corp Plc (アマリン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アマリン(Amarin Corporation plc)は心血管疾患の治療を中心とする脂質科学の専門知識を持つ後期臨床試験段階のバイオ医薬品会社。同社の製品候補「AMR101」は超高純度オメガ3脂肪酸である。同社はトリグリセリド値の高い患者または高トリグリセリド血症患者を治療するための薬品「AMR101」を開発している。平成23年9月、同社は米国食品医薬品局(FDA)に新薬承認申請(NDA)を提出した。平成23年12月、同社は「REDUCE-IT」というタイトルが付けられた「AMR101」の心血管成果試験(イコサペンタエン酸(EPA)及び心血管事故の減少という介入試験)での患者への投薬を開始した。   アマリンは英国のバイオ医薬品メ―カ―。循環器疾患の治療に焦点を当てた治療薬の研究、開発、商業化に従事。主力製品の「Vascepa」カプセルは、重度の高トリグリセリド血症の成人患者向けの治療薬で、米国食品医薬品局(FDA)の承認を取得。エイコサベンタエン酸のエチルエステルを高純度で含む。本社はアイルランド。   Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
本社所在地 2 Pembroke House Upper Pembroke Street 28-32 Dublin Ballsbridge 2 IRL
代表者氏名 Lars G. Ekman ラース・エックマン
代表者役職名 Independent Chairman of the Board
電話番号 +353 1-669-9020
設立年月日 32568
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 241人
url www.amarincorp.com
nasdaq_url https://www.nasdaq.com/symbol/amrn
adr_tso 291562458
EBITDA EBITDA(百万ドル) -69.12400
終値(lastsale) 18.9
時価総額(marketcap) 5510530456.2
時価総額 時価総額(百万ドル) 5215.741
売上高 売上高(百万ドル) 197.78800
企業価値(EV) 企業価値(EV)(百万ドル) 5254.872
当期純利益 当期純利益(百万ドル) -84.19700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amarin Corporation plc (ADR) revenues increased 21% to $96.6M. Net loss increased 69% to $58.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 43% to $71.7M (expense) Co-promotion fees increase from $5.2M to $19.4M (expense).

 AMRNのテクニカル分析


 AMRNのニュース

   Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020  2020/07/21 20:15:00 GlobeNewswire
DUBLIN, Ireland and BRIDGEWATER, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a…
   Amarin (AMRN) stock to remain within a tight range until the end of Vascepa litigation  2020/06/25 00:04:28 News Alphastreet
The patent war between Amarin (NASDAQ: AMRN) and the generic companies for cardiovascular drug Vascepa continues to be a headwind for Amarin. Shares of the clinical biotechnology company were shattered at the end of March after the Nevada Court ruled in favor of two generic companies in the patent litigation case related to the generic […]
   Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'  2020/06/17 15:52:56 Benzinga
Amarin Corporation plc (NASDAQ: AMRN ) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa. The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price target. Stifel analyst Derek Archila reiterated a Hold rating. SVB Leerink analyst Ami Fadia has an Outperform rating and $9 price target. Settlement Could Move Sentiment For Amarin: The settlement agreement is good news, especially as it comes after Amarin lost the case with two other generic manufacturers, Hikma and Dr.Reddy's Laboratories Ltd (NYSE: RDY ), Cantor's Chen said in a Tuesday note. If Apotex felt it had a chance, it would have waited a few months for a near-term opportunity rather than waiting until 2029, the analyst said. Amarin is appealing a patent invalidity ruling from March to the U.S. Court of Appeals, she said. "We think this settlement could potentially move sentiment toward a potential win for AMRN." The settlement prevents Apotex from selling a generic version of Vascepa in the U.S. …
   The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked  2020/06/17 07:30:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hour. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) ADC …
   Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc.  2020/06/16 20:30:00 GlobeNewswire
DUBLIN, Ireland and BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today a settlement agreement with…
   Amarin (AMRN) stock to remain within a tight range until the end of Vascepa litigation  2020/06/25 00:04:28 News Alphastreet
The patent war between Amarin (NASDAQ: AMRN) and the generic companies for cardiovascular drug Vascepa continues to be a headwind for Amarin. Shares of the clinical biotechnology company were shattered at the end of March after the Nevada Court ruled in favor of two generic companies in the patent litigation case related to the generic […]
   Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'  2020/06/17 15:52:56 Benzinga
Amarin Corporation plc (NASDAQ: AMRN ) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa. The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price target. Stifel analyst Derek Archila reiterated a Hold rating. SVB Leerink analyst Ami Fadia has an Outperform rating and $9 price target. Settlement Could Move Sentiment For Amarin: The settlement agreement is good news, especially as it comes after Amarin lost the case with two other generic manufacturers, Hikma and Dr.Reddy's Laboratories Ltd (NYSE: RDY ), Cantor's Chen said in a Tuesday note. If Apotex felt it had a chance, it would have waited a few months for a near-term opportunity rather than waiting until 2029, the analyst said. Amarin is appealing a patent invalidity ruling from March to the U.S. Court of Appeals, she said. "We think this settlement could potentially move sentiment toward a potential win for AMRN." The settlement prevents Apotex from selling a generic version of Vascepa in the U.S. …
   The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked  2020/06/17 07:30:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hour. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) ADC …
   Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc.  2020/06/16 20:30:00 GlobeNewswire
DUBLIN, Ireland and BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today a settlement agreement with…
   Why Some Analysts Remain Bullish on Amarin Stock  2020/06/16 15:38:43 24/7 Wall street
   INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm  2020/03/31 22:19:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $AMRN #AMRN--INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation plc.
   Amarin News: AMRN Stock Plunges 71% on Court Ruling  2020/03/31 19:38:11 InvestorPlace
Amarin (AMRN) news for Tuesday concerning a generic rival lawsuit over one of its drugs has AMRN stock taking a nosedive.
   Amarin's Stock Plunges Following Unfavorable Patent Ruling  2020/03/31 14:12:00 Zacks Investment Research
Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.
   Amarin shares Tank on Losing Court Ruling on Vascepa  2020/03/31 13:38:32 Baystreet.ca
Amarin Corporation plc (NASDAQ:AMRN) early Tuesday as the court ruled against its patent for heart treatment drug Vascepa. The United States District Court for the District of Nevada in Las Vegas ruled that six patents on Vascepa, which were all …
   Amarin's stock plummets on heavy volume after court rules in favor of makers of generic Vascepa  2020/03/31 12:49:00 MarketWatch
Shares of Amarin Corp. PLC took a 69% dive on heavy volume in premarket trading Tuesday, after drug maker announced a disappointing court ruling in its…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アマリン AMRN Amarin Corporation plc)

 twitter  (公式ツイッターやCEOツイッターなど)